# Radioablation With or Without Androgen DeprIvation Therapy in Metachronous Prostate Cancer OligometaStAsis

> **NCT03940235** · PHASE2 · UNKNOWN · sponsor: **European Institute of Oncology** · enrollment: 150 (estimated)

## Conditions studied

- Oligometastatic Prostate Cancer

## Interventions

- **DRUG:** Androgen deprivation therapy (ADT)
- **RADIATION:** SBRT

## Key facts

- **NCT ID:** NCT03940235
- **Lead sponsor:** European Institute of Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-01
- **Primary completion:** 2023-12-01
- **Final completion:** 2024-04-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2023-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03940235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03940235, "Radioablation With or Without Androgen DeprIvation Therapy in Metachronous Prostate Cancer OligometaStAsis". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT03940235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*